Bausch Health (NYSE:BHC) announced today that it initiated a clinical trial program in Canada to investigate the use of Virazole for treating COVID-19.

With today’s announcement, Bausch joins Eli Lilly (NYSE:LLY) and Care Access Research, which both announced clinical testing of coronavirus therapies last week.

Bausch’s Virazole is currently approved in the U.S. and Canada, among other countries around the world, for treating hospitalized infants and young children with severe lower respiratory tract infections as a result of respiratory syncytial virus (RSV).

Get the full story at our sister site, Drug Discovery & Development